Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common antifungal drug slow prostate Cancer's return?

NCT ID NCT07365423

Recruiting now Disease control Sponsor: Swiss Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 4 times

Summary

This phase II trial is testing whether terbinafine, a widely used antifungal pill, can slow the rise of PSA in men whose prostate cancer has returned after initial treatment. The goal is to see if this well-tolerated drug can delay or replace standard hormone therapy, which often causes significant side effects. The study will enroll 42 men with biochemical recurrence and no visible tumors on scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Terbinafine (an antifungal drug)
What this could lead to
If it works, this could offer a well-tolerated, oral option to delay or avoid hormone therapy in men with early prostate cancer recurrence.
What could go wrong
This is a small, early-phase trial (42 participants) testing a repurposed drug. The anti-cancer effect is not proven, and the primary endpoint is only a PSA marker, not survival or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT PROSTATE CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • EOC - Istituto Oncologico della Svizzera Italiana

    RECRUITING

    Bellinzona, 6500, Switzerland

  • HOCH Health Ostschweiz - Kantonsspital St. Gallen

    RECRUITING

    Sankt Gallen, 9007, Switzerland

  • Hôpitaux Universitaires Genève HUG

    RECRUITING

    Geneva, 1211, Switzerland

  • Kantonsspital Baden

    RECRUITING

    Baden, 5404, Switzerland

  • Kantonsspital Graubünden

    RECRUITING

    Chur, 7000, Switzerland

  • Kantonsspital Winterthur

    RECRUITING

    Winterthur, 8401, Switzerland

  • Luzerner Kantonsspital

    RECRUITING

    Lucerne, 6004, Switzerland

  • Spital Thurgau AG

    RECRUITING

    Frauenfeld, 8501, Switzerland

  • TBZO Tumor- und BrustZentrum Ostschweiz - Rapperswil

    RECRUITING

    Rapperswil, 8640, Switzerland

  • Universitätsspital Basel

    RECRUITING

    Basel, 4031, Switzerland

  • Universitätsspital Zürich USZ

    RECRUITING

    Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.